MEC Basic – MyMedflix Member Portal

Caring for ALS: What I Wish I knew

Caring for ALS: What I Wish I knew

Melissa Alice Jones, PA

Changing Landscape of Therapeutic Development for Genetic ALS & All ALS

Changing Landscape of Therapeutic Development for Genetic ALS & All ALS

Suma Babu, MD, MPH, MBBS

National ALS Registry & Upcoming Research

National ALS Registry & Upcoming Research

Reshma Punjani, MPH

Diagnosing ALS | Understanding ALS

Diagnosing ALS | Understanding ALS

Gustavo Alameda, MD, FAAN

Radiating Salivary Glands in Patients with ALS for Sialorrhea

Radiating Salivary Glands in Patients with ALS for Sialorrhea

Lav Goyal, MD, MBA

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

Benjamin Levy, MD

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

Paul Frankel, PhD

Current Status of Biosimilars and Recent Approvals

Current Status of Biosimilars and Recent Approvals

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

How to Manage Myelodysplasia: Biomarkers and Novel Treatments

How to Manage Myelodysplasia: Biomarkers and Novel Treatments

Guillermo Garcia-Manero, MD

Tumor Biology, Pathology, Novel Diagnostics

Tumor Biology, Pathology, Novel Diagnostics

Tianhong “Tina” Li, MD, PhD

Biosimilars Implementation in the US: A Five Year Review

Biosimilars Implementation in the US: A Five Year Review

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

Alberto Chiappori, MD

Novel Frontiers in the Use of ctDNA in Oncology

Novel Frontiers in the Use of ctDNA in Oncology

Julia Rotow, MD

Moving ctDNA Utilization Beyond Predictive Biomarkers: The Next Frontier

Moving ctDNA Utilization Beyond Predictive Biomarkers: The Next Frontier

Christian Rolfo, MD, PhD, MBA, Dr.hc

Predictive Biomarkers for Immunotherapy - Non-Small Cell Lung Cancer (NSCLC) as a Model of Tumor Heterogeneity

Predictive Biomarkers for Immunotherapy - Non-Small Cell Lung Cancer (NSCLC) as a Model of Tumor Heterogeneity

David R. Gandara, MD

Biosimilars Implementation in the United States: Where Opportunities Remain

Biosimilars Implementation in the United States: Where Opportunities Remain

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains

Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains

Jorge J. García, PharmD, MS, MHA, MBA, FACHE

How Far Have We Gone with Biosimilars?

How Far Have We Gone with Biosimilars?

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

The Challenges of Biosimilars in the Daily Oncology Practice?

The Challenges of Biosimilars in the Daily Oncology Practice?

Dina B. Dumercy McHenry, PharmD, MBA, BCOP

Clinical Update: Biosimilars to Adalimumab

Clinical Update: Biosimilars to Adalimumab

Johnny Chang, PharmD, BCPS, CSP

Moving the Needle on Bladder Cancer Survival - a Urologist’s Perspective

Moving the Needle on Bladder Cancer Survival - a Urologist’s Perspective

Marc Dall'Era, MD

Bladder Cancer Updates

Bladder Cancer Updates

Petros Grivas, MD, PhD

Bladder Cancer Updates

Bladder Cancer Updates

Petros Grivas, MD, PhD

Bladder / Urothelial Cancer Updates

Bladder / Urothelial Cancer Updates

Petros Grivas, MD, PhD

Bladder Cancer Update

Bladder Cancer Update

Benjamin Garmezy, MD